- Home
- MLNK vs HROW Comparison
MLNK vs HROW Comparison
Compare MLNK & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- HROW
- Stock Information
- Founded
- MLNK 1998
- HROW 1998
- Country
- MLNK United States
- HROW United States
- Employees
- MLNK N/A
- HROW N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- HROW Health Care
- Exchange
- MLNK Nasdaq
- HROW Nasdaq
- Market Cap
- MLNK 1.3B
- HROW 1.1B
- IPO Year
- MLNK 2021
- HROW N/A
- Fundamental
- Price
- MLNK $19.81
- HROW $38.82
- Analyst Decision
- MLNK Hold
- HROW Strong Buy
- Analyst Count
- MLNK 8
- HROW 7
- Target Price
- MLNK $21.21
- HROW $64.67
- AVG Volume (30 Days)
- MLNK 1.3M
- HROW 646.6K
- Earning Date
- MLNK 08-11-2025
- HROW 08-11-2025
- Dividend Yield
- MLNK N/A
- HROW N/A
- EPS Growth
- MLNK N/A
- HROW N/A
- EPS
- MLNK N/A
- HROW N/A
- Revenue
- MLNK $325,891,000.00
- HROW $227,661,000.00
- Revenue This Year
- MLNK $6.21
- HROW $46.17
- Revenue Next Year
- MLNK $5.66
- HROW $39.97
- P/E Ratio
- MLNK N/A
- HROW N/A
- Revenue Growth
- MLNK 5.96
- HROW 47.69
- 52 Week Low
- MLNK $15.49
- HROW $20.85
- 52 Week High
- MLNK $25.33
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- MLNK 74.95
- HROW 65.04
- Support Level
- MLNK $19.75
- HROW $29.75
- Resistance Level
- MLNK $19.85
- HROW $38.15
- Average True Range (ATR)
- MLNK 0.33
- HROW 2.47
- MACD
- MLNK 0.44
- HROW 0.46
- Stochastic Oscillator
- MLNK 99.07
- HROW 83.52
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.